FDA Extends Review Period for Savara's Lead Asset Molgramostim
Savara (SVRA) has received an extension of three months from the FDA for the review of its marketing application for molgramostim inhalation solution, its lead asset. The extension was granted after the company resubmitted its biologics license application. This delay may impact the timeline for potential approval and market entry of the drug.
Tickers: $SVRA
Topics: drug approval FDA molgramostim Savara